These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
177 related articles for article (PubMed ID: 36866728)
1. Advances in inhaled antibiotics for management of respiratory tract infections. Riveiro V; Casal A; Abelleira R; Valdés L Curr Opin Pulm Med; 2023 May; 29(3):160-167. PubMed ID: 36866728 [TBL] [Abstract][Full Text] [Related]
2. Novel amikacin inhaled formulation for the treatment of lower respiratory tract infections. Antoniu S; Azoicai D Drugs Today (Barc); 2013 Nov; 49(11):683-92. PubMed ID: 24308015 [TBL] [Abstract][Full Text] [Related]
3. The efficacy and safety of inhaled antibiotics for the treatment of bronchiectasis in adults: a systematic review and meta-analysis. Laska IF; Crichton ML; Shoemark A; Chalmers JD Lancet Respir Med; 2019 Oct; 7(10):855-869. PubMed ID: 31405826 [TBL] [Abstract][Full Text] [Related]
4. [Chinese experts consensus statement: diagnosis and treatment of cystic fibrosis (2023)]. ; ; Zhonghua Jie He He Hu Xi Za Zhi; 2023 Apr; 46(4):352-372. PubMed ID: 36990700 [TBL] [Abstract][Full Text] [Related]
5. Inhaled antibiotics in Cystic Fibrosis (CF) and non-CF bronchiectasis. Tay GT; Reid DW; Bell SC Semin Respir Crit Care Med; 2015 Apr; 36(2):267-86. PubMed ID: 25826593 [TBL] [Abstract][Full Text] [Related]
6. Inhaled antibiotics for lower airway infections. Quon BS; Goss CH; Ramsey BW Ann Am Thorac Soc; 2014 Mar; 11(3):425-34. PubMed ID: 24673698 [TBL] [Abstract][Full Text] [Related]
7. Inhaled amikacin for treatment of refractory pulmonary nontuberculous mycobacterial disease. Olivier KN; Shaw PA; Glaser TS; Bhattacharyya D; Fleshner M; Brewer CC; Zalewski CK; Folio LR; Siegelman JR; Shallom S; Park IK; Sampaio EP; Zelazny AM; Holland SM; Prevots DR Ann Am Thorac Soc; 2014 Jan; 11(1):30-5. PubMed ID: 24460437 [TBL] [Abstract][Full Text] [Related]
8. Oral versus inhaled antibiotics for bronchiectasis. Spencer S; Felix LM; Milan SJ; Normansell R; Goeminne PC; Chalmers JD; Donovan T Cochrane Database Syst Rev; 2018 Mar; 3(3):CD012579. PubMed ID: 29587336 [TBL] [Abstract][Full Text] [Related]
14. Inhaled antibiotics in the treatment of non-cystic fibrosis bronchiectasis: clinical and drug delivery perspectives. Sugianto TD; Chan HK Expert Opin Drug Deliv; 2016; 13(1):7-22. PubMed ID: 26289675 [TBL] [Abstract][Full Text] [Related]
15. The Rationale and Evidence for Use of Inhaled Antibiotics to Control Pseudomonas aeruginosa Infection in Non-cystic Fibrosis Bronchiectasis. Dhand R J Aerosol Med Pulm Drug Deliv; 2018 Jun; 31(3):121-138. PubMed ID: 29077527 [TBL] [Abstract][Full Text] [Related]
16. Assessing effects of inhaled antibiotics in adults with non-cystic fibrosis bronchiectasis--experiences from recent clinical trials. Paredes Aller S; Quittner AL; Salathe MA; Schmid A Expert Rev Respir Med; 2018 Sep; 12(9):769-782. PubMed ID: 30025482 [TBL] [Abstract][Full Text] [Related]
18. The Use of Amikacin Liposome Inhalation Suspension (Arikayce) in the Treatment of Refractory Nontuberculous Mycobacterial Lung Disease in Adults. Khan O; Chaudary N Drug Des Devel Ther; 2020; 14():2287-2294. PubMed ID: 32606598 [TBL] [Abstract][Full Text] [Related]
19. Inhaled antibiotics for lower respiratory tract infections: focus on ciprofloxacin. Serisier DJ Drugs Today (Barc); 2012 May; 48(5):339-51. PubMed ID: 22645722 [TBL] [Abstract][Full Text] [Related]